The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.
Age 18-80
Hystologicaly proven gastric adenocarcinoma
ECOG status 0-1
Written consent to participate in the study
Pregnancy/breastfeeding
ECOG status 2-4
Concomitant malignancy
Mitomycin and/or Cisplatin hypersensitivity
The study population will consist of adult patients receiving care at oncological centers in Ukraine who meet all predefined eligibility criteria for this study. Investigators include individuals with for which Gastrectomy+HIPEC is considered an accepted or potentially beneficial treatment option according to national and international clinical guidelines. Participants will be recruited from tertiary surgical oncology hospitals and specialized cancer institutes across Ukraine.
Cohort
Prospective
curative-intent surgery + HIPEC
Procedure/SurgeryParticipants enrolled in this study will undergo curative-intent gastrectomy for gastric cancer, immediately followed by Hyperthermic Intraperitoneal Chemotherapy (HIPEC) performed during the same operative session. Dosage of drugs: mitomycin C 15 mg/m2, cisplatin 75mg/m2. The procedure is conducted according to a standardized protocol in National Cancer Institute
Peritoneal recurrence rate
Number of patients developed peritoneal recurence
Distant recurrence rate
Time from diagnosis to distant reccurence
Intraperitoneal chemotherapy complications rate
Complications rate assessed by Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 (Grade from 1 to 5)
Postoperative complications rate
Complications rate assessed by Clavien-Dindo scale (Grade from 1 to 5)
5-years overall survival
5-years overall survival
Click on the lead sponsor to view all of their trials.
